Antisense oligonucleotides, complementary to certain gene sequences, are designed to hybridize to mRNA and inhibit the synthesis of disease related cellular or viral proteins (1) (2) (3) . Although numerous in vitro studies have established a great deal of therapeutic potential for these oligonucleotides, there are still many unresolved properties of these oligomers which are critical to drug development. Methylphosphonate and phosphorothioate oligonucleotides are among the most nuclease-resistant oligomers that still maintain the properties of natural DNA. In order to develop these potential drugs as a clinical entity, it is essential to study the biodistribution and biostability. Labelled oligonucleotides can be used as tools for in vivo distribution studies. The radiolabelled oligomers which have been used in the past are mostly labelled at problematic sites at the end of oligonucleotide. Phosphodiester and phosphorothioate oligomers were generally labeled by polynucleotide kinase which transfers [ 32 P]phosphate group from ATP to the 5'-end of the oligomer (4, 5) . In the case of methylphosphonate oligomers a tritiated thymidine has been attached to the 5'-end through an enzymatically labile phosphodiester linkage (6) . These types of labeling methods make it difficult to draw a meaningful conclusion from metabolic studies since the label can be readily cleaved from the oligonucleotide in vivo.
More reliable data has been obtained using uniformly labeled [
35 S]phosphorothioate oligonucleoides, however, the utility of this type of labeling is limited to the phosphorothioate backbone (7) . Recently, Sands and co-workers (8) reported an enzymatic radiolabelling of oligonucleotides by 3 H-methylation of an internal deoxycytidine with Hhal methylase and S-[ 3 H]adenosylmethionine. Although this type of labeling is ideal for biodistribution and stability studies, this procedure requires synthesis of a complementary sense oligonucleotide which is made preferably with 5-methyldeoxycytidine to prevent tritiation of sense oligomer. In addition, it is not known if this procedure can be utilized for labeling methylphosphonate oligomers.
We report here the synthesis of suitably protected tritiumlabelled methylphonate monomers of deoxyadenosine, deoxyguanosine, deoxycytidine and thymidine that can be incorporated at any position within the oligomer sequence. In addition, these monomers can be coupled to the 5'-end of the oligomer of any backbone including methylphosphonate, phosphorothioate and phosphodiester oligomer with limited or no adverse effect on the properties of oligonucleotide. With incorporation of the 5'-tritiated monomer the oligonucleotide is protected from digestion by 5'-exonucleases.
Methy lphosphonous dichloride was used for the synthesis of all four nucleoside methylphosphonamidites. The large scale synthesis of methy lphosphonous dichloride was reported in 1977 by Soroka (9) . With slight modification of this procedure it was possible to synthesize tritiated methylphosphonous dichloride (methyl-CT3) in relatively good yield.
Phosphorous(III) chloride, was methylated using freshly prepared tritiated iodomethane (ICT3) in a specifically designed vacuum line that prevents tritium contamination. The reaction and distillations were carried out under chilled condition as explained in the methods below. The overall yield of the desired product after distillation was >90%, which yielded enough material to synthesize 2 Ci of each monomer with specific activity around 700 mCi/mmole (Scheme 1).
The synthesis of nucleoside-3'-(iV,iV-diisopropyl-methylphosphonamidite has been reported by coupling methylphosphonous dichloride with the 3'-hydroxy of nucleosides Methylphosphonous dichloride must be converted to either methyl-diisopropylaminochlorophosphine or methyl-[bis-diisopropylamino]-phosphine for coupling to nucleoside. Methyl-[bis-diisopropylamino]-phosphine, although a solid and more stable compound is difficult to obtain in adequately pure form for efficient coupling. Methyl-diisopropylamino-chlorophophine is the most commonly used procedure in our laboratory. It requires one more step of purification of a volatile and pyrophoric material which is even more challenging for the synthesis of tritiated compound. Consequently, in situ preparation of methyl-diisopropylamino-chlorophosphine was the most applicable method for the synthesis of monomer synthons. As a result, the synthesis of tritiated adenosine, guanosine, cytidine and thymidine monomers were accomplished using this chemistry as described above (Scheme 1).
Anhydrous acetonitrile was used as common solvent for most of the reactions. In order to avoid tritium contamination, methyl-fCry-phosphonous dichloride, was transfered into the * To whom correspondence should be addressed reaction flask using a sealed manifold at -197°C. In situ preparation of methyl-[CT3]-diisopropylamino-chlorophosphine, was carried out separately for each monomer synthesis prior to nucleoside addition. The nucleosides were dissolved in acetonitrile and mixed with trialkylamine and added to methyHCTy-diisopropylaminochlorophosphine solution at -20°C. After the completion of reaction and removal of the solvent, the product was purified by flash column chromatography on silica gel. Since silica gel, being acidic in nature, can potentially activate the rnethylphosphonamidite monomer and hydrolyze it to a H-phosphinate. To avoid hydrolysis, it is important to pre-treat the silica gel with a weak base such as 2% triethylamine in hexane/ethyl acetate (1:1) and add 0.5-1% triethylamine to the eluent. Even under these conditions, it is essential to limit the contact time of monomer with the silica gel to <20 min.
The protected nucleosides were provided by JBL Scientific San Luis Obispo, CA. All other chemicals were purchased from Aldrich Chemical company, Saint Louis, MO.
Methyl[CTj]phosphonous dichloride (1):
Into a dry 50 ml two neck round bottom flask, fitted with a dry ice condenser, stir bar and septum, was added 4.55 g (34.1 mmol) anhydrous aluminum chloride under argon. The flask condenser was attached to a vacuum line by way of a 15 cm bridge. Phosphorous(III) chloride, 3.2 ml (30.1 mmol) was added via syringe and the mixture was heated at 65-75°C for 30 min. The vessel was cooled to -78°C and fully evacuated. A break seal flask containing freshly prepared tritiated iodomethane (ICT 3 ), 4.27 g (30.1 mmol, 24 Ci) was attached to the bridge. The reaction vessel was cooled to -197°C in liquid nitrogen and ICT3 was transferred under static vacuum. The mixture was warmed to -80°C for 5 min and further warmed to 0°C for 2 h with continuous stirring. Volatiles were removed from the reaction mixture under vacuum at 0°C and vacuum trapped at -197°C. The reaction vessel was then cooled to -78°C and returned to atmospheric pressure with dry argon. A mixture of potassium chloride, 2.54 g (34.1 mmol) and iron powder, 1.8 g (32.2 mmol) was added. The product along with iodine was slowly flame distilled under vacuum into a receiving flask at -197°C. Following several vacuum distillations, clear, iodine free, methylphosphonous dichloride [methy-CT3), 3.91 g, (91% yield) was obtained. The specific activity of this compound was determined after the coupling with nucleosides and found to be 731 mCi/mmol.
5' -Dimethoxytrityl-N 4 -isobutyryl-2' -deoxycytidine-3' -(N,N-diisopropyl-methyl[CT^]phosphonamidite (2):
A dry 3-neck 50 ml round bottom flask fitted with two rubber septa and magnetic stir bar was attached to a vacuum manifold. The manifold was also equipped with a 100 ml flask and a breakseal containing methyl-[CT3]-phosphonous dichloride, 554 mg (4.74 mmol, 3.46 Ci). The entire system was evacuated and under static vaccum, methyl-[CT3]-phosphonous dichloride, was transferred into the reaction vessel at -197°C. The flask was isolated from the manifold and warmed to room temperature. Anhydrous acetonitrile, 20 ml, was added by syringe through the septum and the mixture was cooled to -20°C followed by the addition of diisopropylamine, 1.54 ml (11.02 mmol). After mixing at -20°C for 20 min the white suspension, containing methyl-[CT3]-diisopropylamino-chlorophosphine, was treated with an anhydrous solution of 2.9 g, (4.6 mmol) A^-isoburyryl-5'-dimethoxytrityl-2'-deoxycytidine in 5.0 ml acetonitrile and 0.9 ml of triethylamine. The mixture was warmed to room temperature and stirred for 40 min. The reaction vessel was opened to the manifold and volatiles were distilled into an evacuated 100 ml flask at -197°C. The residue was redissolved in hexane/ethyl acetate (1:1), assayed and found to contain 3. . Purity >95% by TLC and HPLC. Product identity was confirmed by co-chromatogra-phy with an authentic cold sample. Specific activity 719 mCi/mmol. UV max (CH 3 CN) 281 nm (e 13 000).
5'-Dimethoxytrityl-thymidine-3'-(N,N-diisopropyl-methylphosphonamidite [methyl-CTs] (4):
Following the procedure of dC-MAP-[methyl-CT 3 ], 4.81 mmole, (3.52 Ci) of methylphosphonous dichloride [methyl-CT3], and 4.74 mmol of 5'-dimethoxytrityl-thymidine were used. The crude material was purified by a similar flash chromatography system.The yield was 3.7 mmol (78% chemical yield) which contained 2.76 Ci (77% radiochemical yield). Product identity was confirmed by co-chromatography with authentic cold standard. Purity 97% by TLC on silica gel eluted with the purification solvent system, Rf -0.8. Specific activity 737 mCi/mmol, UV max (CH 3 CN) 265 nm (e 13 900). (5) The oligomer was synthesized on a Biosearch 8900 Expedite DNA synthesizer using the following general techniques:
The methylphosphonate oligomer was synthesized using protocols described for the coupling of methylphosphonamidites (10) . The coupling programs for methylphosphonate at 15 |imol quanity was adjusted for best coupling efficiency. The n-1 sequence of the desired oligomer was synthesized by Expedite. A tritiated T-MAP monomer was then coupled to the 5'-end by manual methods using syringes to push reagents through the solid support. The manual method was chosen to avoid tritium contamination of the automated synthesizer. First the efficiency of the manual coupling method was verified by using non-tritiated monomers and then the procedure was repeated identically with tritiated monomers.
Dry solid support was removed from the synthesis column and placed into a 10 ml screw top vial and deprotected by one-pot procedure and desalted on a C-18 Sep-Pak column as described elsewhere (11) .
The oligomer was purified on a semi-preparative Cyclobond HPLC column. About 500 ODs of crude oligomer was loaded on the column per run and eluted with 60% isocratic CH 3 CN/50 mM ammonium acetate. The oligomer pool was collected and dried down on a speed-vac. Two co-evaporations with water was sufficient to remove the ammonium acetate from the oligomer. Each 15 |imol synthesis normally yields 1500-2000 OD units of crude materials at 260 nm. The non-tritiated oligomer was further analyzed by mass spectroscopy using electro spray ionization (ESI). The tritiated oligomer was further analyzed by HPLC spike of the non-tritiated and side by side PAGE analysis.
In summary, tritiated monomers are stable forms of a tritium labeled moiety which can be efficiently incorporated at any position of oligonucleotide methylphosphonate. The stability of C-P bond in methylphosphonate oligomer has been observed in our laboratory under physiological conditions as well as general chemical reaction conditions used in oligonucleotide chemistry. In addition, the MP-oligomer backbone is one of the most stable forms of modified oligonucleotide to DNA cleaving and DNA processing enzymes. Furthermore, it is also possible to incorporate tritiated methylphosphonate into phosphorothioates, phosphodiesters and other backbone modified oligonucleotides with little or no change in the hybridization and uptake properties of the oligomers.
